Citadel Advisors’s PHAXIAM Therapeutics S.A.. American Depositary Shares PHXM Stock Holding History

Citadel Advisors’s Portfolio PHXM Stock Details PHXM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10	Closed	-$98	–	15516
2023 Q1	$98	Buy	+10	New	+$77	﹤0.01%	14589

Other funds holding PHXM

ADL

Asset Dedication LLC San Francisco, California $1.59B AUM 26.56% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's PHXM Position: Q3 2023 in Review

Citadel Advisors sold out of PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) in Q3 2023, closing a stake of 1,661 shares — an estimated $12.1K sold.

Citadel Advisors first reported a position in PHXM in Q1 2021 and held it in 9 quarters. The position peaked at $173K in Q4 2021. 3 funds tracked by Wall St. Rank hold PHXM as of Q3 2023.

Citadel Advisors reported no remaining PHAXIAM Therapeutics S.A.. American Depositary Shares position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 1,661 PHAXIAM Therapeutics S.A.. American Depositary Shares shares in Q3 2023, an estimated $12.1K.
Citadel Advisors first reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares in Q1 2021 and held it in 9 quarters.
Citadel Advisors's PHAXIAM Therapeutics S.A.. American Depositary Shares position peaked at $173K in Q4 2021.
3 funds tracked by Wall St. Rank held PHAXIAM Therapeutics S.A.. American Depositary Shares as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.